NCT04728724 is a Phase 2 clinical trial of Sintilimab in Non-small Cell Lung Cancer Stage III, sponsored by Shanghai Pulmonary Hospital, Shanghai, China.

Who is sponsoring NCT04728724?

NCT04728724 is sponsored by Shanghai Pulmonary Hospital, Shanghai, China.

What drugs are being tested in NCT04728724?

Interventions in NCT04728724: Sintilimab, Chemotherapy.

What condition does NCT04728724 study?

NCT04728724 studies Non-small Cell Lung Cancer Stage III.

Is NCT04728724 still recruiting?

NCT04728724 is currently recruiting now. Last updated 13 September 2023.

Last reviewed 2023-09-13 · How we verify

NCT04728724

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Neoadjuvant Immunotherapy for Stage III Non-small Cell Lung Cancer

Recruiting now Phase 2 Last updated 13 September 2023

What this trial tests

Phase 2 trial testing Sintilimab in Non-small Cell Lung Cancer Stage III in 100 participants. Currently enrolling.

Timeline

10 September 2022

Primary endpoint
15 September 2023

31 December 2027

Quick facts

Lead sponsor	Shanghai Pulmonary Hospital, Shanghai, China
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	100
Start date	10 September 2022
Primary completion	15 September 2023
Estimated completion	31 December 2027
Sites	1 location across China

Drugs / interventions tested

Sintilimab — full drug profile →
Chemotherapy (chemotherapy) — full drug profile →

Conditions studied

Non-small Cell Lung Cancer Stage III — all drugs for Non-small Cell Lung Cancer Stage III →

Sponsor

Shanghai Pulmonary Hospital, Shanghai, China

Who can join

Adults 18 to 75, any sex, with Non-small Cell Lung Cancer Stage III. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a phase II, non-randomized, open-label, multi-center study to evaluate the efficacy of neoadjuvant Sintilimab (PD-1 antibody) or combined with chemotherapy as first-line treatment in patients with stage III non-small cell lung cancer (NSCLC).

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting nucleotide metabolism: a promising approach to enhance cancer immunotherapy.
Wu HL, Gong Y, Ji P, Xie YF, et al · · 2022 · cited 123× · PMID 35477416 · DOI 10.1186/s13045-022-01263-x
Emerging precision neoadjuvant systemic therapy for patients with resectable non-small cell lung cancer: current status and perspectives.
Godoy LA, Chen J, Ma W, Lally J, et al · · 2023 · cited 34× · PMID 36650586 · DOI 10.1186/s40364-022-00444-7
Neoadjuvant treatment in non-small cell lung cancer: New perspectives with the incorporation of immunotherapy.
Aguado C, Chara L, Antoñanzas M, Matilla Gonzalez JM, et al · · 2022 · cited 23× · PMID 35662985 · DOI 10.5306/wjco.v13.i5.314
Conversion therapy with immunotherapy plus chemotherapy achieves a pathological complete response in stage IIIC NSCLC.
Fu Y, Duan W, Xu R, Chen J. · · 2023 · cited 1× · PMID 38022567 · DOI 10.3389/fimmu.2023.1268153
Progress in perioperative immunotherapy for lung cancer and analysis of therapy (Review).
Ma X, Li G, Li H, Li L, et al · · 2026 · PMID 41560977 · DOI 10.3892/ol.2026.15453
Efficiency and safety of sintilimab-based induction therapy in potentially resectable stage III non-small cell lung cancer (LungMate-009): an open-label, phase 2 trial.
Ge T, Zhang H, Zhu X, Teng M, et al · · 2025 · PMID 41477564 · DOI 10.1016/j.eclinm.2025.103669

Verify or expand the search:

Other trials of Sintilimab

Trials testing the same drug.

NCT07535632 — SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cance · Phase 2 · not yet recruiting
NCT07537946 — Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer · Phase 3 · not yet recruiting
NCT07537972 — Denosumab Strategy for Liver Cancer With Bone Metastases · Phase 2 · not yet recruiting
NCT07468630 — Tolecizumab Plus Chemoimmunotherapy for pMMR/MSS Locally Advanced Colon Adenocarcinoma · Phase 2 · recruiting
NCT07515625 — Efficacy of Sintilimab Combined With Bevacizumab and XELOX/SOX in Initially Unresectable AFP-positive Gastric/Gastroesop · Phase 2 · not yet recruiting

Other recruiting trials for Non-small Cell Lung Cancer Stage III

Currently open trials in the same condition.

NCT06908070 — Chemoradiotherapy With Surgery Followed by Consolidation Durvalumab · Phase 4 · recruiting
NCT06634199 — Study of Antitumor Immune Response After cCRT and IO Treatment in Non-resectable III Stage NSCLC Patients · recruiting
NCT05557552 — Sequential Chemo-immunotherapy Plus Thoracic Radiotherapy for Elderly And/or Frail Stage III Non-small-cell Lung Cancer · NA · recruiting
NCT05398094 — Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy · Phase 2 · recruiting
NCT04685070 — Neoadjuvant HS-10296 (Almonertinib) Therapy for Potential Resectable Stage III EGFR Mutation-Positive Non-small Cell Lun · Phase 2 · active not recruiting

Other Shanghai Pulmonary Hospital, Shanghai, China trials

Trials by the same sponsor.

NCT07469488 — A Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM) in Chinese Patients With EGFR-M · Phase 4 · not yet recruiting
NCT07494591 — TEAS for Ipsilateral Shoulder Pain After Video-Assisted Thoracoscopic Lung Surgery · NA · not yet recruiting
NCT07517640 — Combining Furmonertinib With Local Therapy for Inoperable Early-stage Lung Cancer: A Phase II Trial · Phase 2 · not yet recruiting
NCT07393438 — Acetohydroxamic Acid Combined With a Short-Course Regimen for MDR-TB (AHA-PLUS) · Phase 2 · not yet recruiting
NCT07375979 — A Multi-modal Integrating Imaging and Cell-free DNA Methylation in Lung Cancer Early Detection (CMe-Lung): a Multi-cente · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04728724 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Pulmonary Hospital, Shanghai, China
Last refreshed: 13 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04728724.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing